<aside> 💡 Notion Tip: Add more details right in this page, including toggles, images, and more. Break up the page by using our different header options so that it’s easier to read. Learn more about different types of content blocks here.
</aside>
The Japan-first and East-Asia-first landscape matters most for PQ because it defines the most relevant alternatives a nursing-home operator, municipality, or research partner would actually see first. The closest local comparators are below.
| Competitor | Country | Product summary | Target customers | Core tech | Regulatory / diagnostic posture | Evidence / validation | East Asia / ASEAN presence | Strengths vs PQ | Weaknesses vs PQ |
|---|---|---|---|---|---|---|---|---|---|
| SOMPO + Palantir | Japan + US | Foundry-based elder-care data and operations platform across SOMPO care facilities; framed around care plans, efficiency, reporting, and risk recommendations | Facility operator, care chain, insurer, government-facing enterprise | Data integration, AI agents, workflow analytics, sensor/data-platform integration | Non-diagnostic enterprise infrastructure | Public deployment since 2020; Palantir says Foundry is used across care facilities in Japan; SOMPO says Palantir supports care transformation; SOMPO also built Future Care Lab as a living lab for elder-care tech | Strong Japan footprint; SOMPO positions solutions for Japan and abroad | Biggest enterprise distribution and operational data layer in Japanese elder care | No public resident engagement device, no neuro-signal layer, no brain-health-specific resident-facing workflow |
| Nippontect Systems / ONSEI | Japan | Voice-based cognitive function monitoring AI; smartphone/app and enterprise versions for local governments and organizations | Municipalities, employers, business/facility programs, healthcare-adjacent users | Voice analysis AI | Explicitly non-medical / non-diagnostic in product disclosures | Clinical-practice paper evaluating ONSEI in dementia-equivalent decline; company states ONSEI Pro is based on AMED-backed work and does not provide medical diagnosis | Japan-focused; no public ASEAN expansion found | Very low-friction Japanese brain-health check; culturally local; fast screening | Mostly an episodic voice check, not a facility-native engagement loop or multisignal care platform |
| Eisai + Cogstate / NouKNOW | Japan + Australia | Self-check digital brain performance test on PC/tablet/smartphone; positioned as a brain-health awareness tool | Consumers, municipalities, insurers, public-health programs | Digital card-test cognitive assessment | Explicitly non-medical / not for prevention or diagnosis | Eisai states NouKNOW is a non-medical device; used in municipal and insurance-linked programs; Cogstate partnership gives Eisai exclusive commercialization rights | Strong Japan distribution through Eisai and insurer/municipality channels | Powerful brand, dementia ecosystem access, low-friction self-check | Primarily periodic self-assessment; no ambient daily facility workflow, no resident-device + edge infrastructure stack |
| Ai-BrainScience | Japan | Eye-tracking cognitive assessment app to digitize dementia/cognitive testing | Clinical, hospital, neurology, diagnostic pathways | Eye tracking + AI | Clinical / diagnostic support; public materials frame it as potential regulated dementia diagnosis support SaMD | Otsuka sales collaboration in Japan; JST and academic publications describe eye-tracking cognitive assessment and tablet clinical validation | Japan-focused; no public ASEAN rollout found | Strong dementia focus, credible academic roots, clinical potential | More clinical and episodic than PQ; higher regulatory complexity; not facility-native daily life |
| Araya | Japan | Neuro-AI / BCI research company developing BMI algorithms and compact wearable EEG with partners | Research labs, neurotech developers, BCI ecosystem | EEG, AI, wearable BMI algorithms | Research-first, not public elder-care product / not public non-diagnostic care service | J-Startup listing; Araya research team says it develops wearable EEG and BCI algorithms; JapanEEG / speech-decoding work signals technical depth | Japan-based; global research ambitions, but no public elder-care deployment found | Strong neuroscience/AI credibility and EEG talent in Japan | Not publicly positioned as a nursing-home product, no care-workflow or facility-native deployment case |
| JiMED | Japan | Wireless implantable BMI medical device for severe neurological disorders / locked-in syndrome | Clinical, hospital, neurosurgery, severe motor impairment | Implantable BMI + AI decoding | Fully medical / implantable | NEDO and KII describe JiMED as developing a wireless implantable BMI medical device; raised Series A in 2025 | Japan clinical/deeptech footprint; no public elder-care deployment | High technical differentiation; shows Japan’s neurotech seriousness | Very far from PQ’s non-diagnostic, non-invasive, facility-native elder-care wedge |
| Neurospace | Japan | ||||||||
| Neeuro | Singapore | SenzeBand 2 EEG headband plus apps/courses for brain training, including senior-focused offerings | Consumer, wellness, training programs, some facility/workshop use | EEG, neurofeedback, cognitive games, ML | Non-invasive wellness / training, not positioned as a medical dementia diagnostic | Official senior-brain-fitness offerings; Tokyo welfare-facility session in 2025; Singapore studies reported improved attention/executive function in seniors | Strong Singapore base; explicit Japan partner activity and Tokyo workshop; Japan partner announcements public | Closest ASEAN-style mix of EEG + games + seniors | Still looks more like training/wellness programming than a nursing-home operations layer with local data infrastructure |
| PENSIEVE-AI | Singapore | Self-administered drawing-based digital pre-dementia test in under 5 minutes | Community screening, health systems, public-health programs | Tablet drawing tasks + AI | Screening / clinical support; not marketed as daily facility ambient monitoring | Nature Communications paper; SGH reports 93% accuracy in nearly 1,800 seniors; rollout in Singapore announced for 2026 | Strong Singapore public-health signal; ASEAN relevance high | Excellent proof that East Asia wants low-burden cognitive screening | Still an episodic test, not a daily care-room intelligence layer |
Two Japan-adjacent names are worth mentioning. Empath is a respected Japanese voice-emotion AI company, but its public positioning is cross-industry emotion recognition rather than brain-health or elder-care infrastructure. Cinnamon is an AI workflow automation company, not a brain-health or neurotech player. Both are better framed as adjacent AI capabilities than direct competitors. Check adjacent entities below to learn more. Also bspr Inc. and BHQ Corp. had released “Braincure” app
The global comparison set is useful because it shows where capital, product categories, and strategic narratives are already moving. These companies overlap with PQ on signal capture, neurofeedback, digital biomarkers, or at-home brain-health workflows, but most are not optimized for nursing-home deployment.
| Competitor | Country | Product summary | Target customers | Core tech | Regulatory / diagnostic posture | Evidence / validation | East Asia / ASEAN signal | Strengths vs PQ | Weaknesses vs PQ |
|---|---|---|---|---|---|---|---|---|---|
| Muse | Canada | Consumer EEG headband for meditation, sleep, focus, and neurofeedback | Consumer, wellness, research | EEG, neurofeedback app | Non-medical consumer/wellness positioning | Officially cites 200+ peer-reviewed studies; used in many research settings | No strong public Japan/ASEAN care deployment found; broad global research footprint | Strong brand recognition and simple EEG hardware | Consumer-first, not nursing-home-native, no operator workflow or facility layer |
| Myndlift | Israel / US-facing | Therapist-guided at-home neurofeedback platform, often paired with Muse hardware | Consumer, therapists, clinics | EEG, app, remote neurofeedback, assessments | Non-invasive neurofeedback / wellness-clinical hybrid; not a dementia care platform | Official site cites peer-reviewed studies; JMIR retrospective study exists | No public East Asia facility rollout found | Strong remote neurofeedback workflow and coaching model | Home use, therapist mediated, not elder-care-facility-native; depends on external headset and active training |
| EMOTIV | US / Australia / Vietnam | Portable EEG hardware and enterprise/research software stack | Research, enterprise, developers, some consumer | EEG hardware, analytics, SDKs, AI | Mostly research/enterprise, with some medical-grade partnerships; not a dementia facility product | Large global EEG install base; official enterprise/research positioning; X-trodes partnership for medical-grade home monitoring research | Strong ASEAN signal via Hanoi/Ho Chi Minh City footprint; global customers | Deep EEG infrastructure and developer ecosystem | Toolkit/platform, not elder-care workflow product; no clear nursing-home wedge |
| Neuroelectrics | Spain | Personalized neuromodulation platform combining EEG and tES/tDCS with software | Clinical, research, therapeutic centers | EEG + tES/tDCS + cloud | Medical / therapeutic orientation | Official therapeutic platform and Asia distributor network | Explicit distributors in Japan, South Korea, Singapore, Malaysia, Hong Kong, Taiwan, China | Serious neurotech credibility and Asia market channels | Treatment-focused and clinically framed, not a non-diagnostic facility signal layer |
| Flow Neuroscience | Sweden | At-home depression treatment headset with app | Consumers, clinics, mental health providers | tDCS + app | Medical device / therapeutic claims | Officially marketed as medically certified; FDA clearance in 2025; RCT in Nature Medicine; NHS usage claims | Japan commercial signal through Kirin investment; Hong Kong and Australia distribution public | Strong medical credibility; home-use neuromodulation | Depression-specific, treatment-oriented, not aging-brain facility workflow |
| Altoida | US / Switzerland heritage | AI/AR digital biomarker platform for early cognitive decline | Clinical, pharma, research, precision neurology | Smartphone/tablet digital biomarkers, AR, ML | Investigational medical device; not cleared for commercial sale | Official site says investigational only; multiple studies and ClinicalTrials.gov entries; Eisai Innovation investment and partnership | Strong Japan signal via Eisai investment; ongoing research partnerships | Most relevant global “digital biomarker for cognition” benchmark | Episodic assessment, investigational/regulatory burden, not nursing-home daily workflow |
| Neurable | US | Brain-signal AI for everyday devices and productivity/wellness interfaces | Consumer, OEMs, enterprise devices | EEG, AI, BCI | Non-medical consumer/OEM platform | Official platform and productization efforts; validation mentions Mayo Clinic and U.S. Air Force in 2026 release | Strong Japan expansion signal via Epson investment and Global Brain support | Strong everyday-device BCI vision; Japan investor support | Focused on general HCI/productivity, not elder care or facility workflows |
| Cognito Therapeutics | US | At-home neurostimulation therapy for Alzheimer’s disease using synchronized light and sound | Clinical, neurology, AD patients | Sensory neurostimulation | Medical / therapeutic, FDA Breakthrough Device Designation | Official pivotal HOPE trial and published feasibility evidence | No strong East Asia commercialization signal found publicly | Strong Alzheimer’s-specific therapeutic narrative and clinical data | Therapeutic path, not non-diagnostic, not facility-native, no daily care-operation layer |
| BrainCo | China / US | BCI products spanning attention training, wellness, education, prosthetics | Consumer, education, BCI markets | EEG, AI, BCI wearables | Mostly non-medical wellness/education plus medical-adjacent prosthetics | Official site and app describe focus/wellness monitoring; company emphasizes scaled hardware manufacturing | Asia-native by default; broad China base; public Japan-specific elder-care signal not found | Large-scale BCI manufacturing and Asian market familiarity | Not elder-care focused; concentration/wellness branding stronger than brain-health care workflow |
| Kernel | US | Wearable brain-measurement / neuroimaging platform and clinic brain-health tracking | Clinics, research, health teams | fNIRS / optical neuroimaging, brain measurement software | Brain-health measurement; closer to clinical/research services than non-diagnostic elder-care ops | Official clinic/tracker products and Flow imaging platform | No strong East Asia expansion signal found publicly | High-quality brain measurement and premium brain-health narrative | Expensive, specialized measurement stack; not nursing-home-native or low-friction bedside workflow |
Here we are showing the subset that explains the category structure. The best axes are:
This is the clearest visual explanation of PQ’s wedge.
quadrantChart
title PQ market positioning
x-axis Consumer / isolated tool --> Facility-native / operator-integrated
y-axis Episodic / clinical --> Daily / continuous
quadrant-1 Facility-native + daily
quadrant-2 Consumer + daily
quadrant-3 Consumer + episodic
quadrant-4 Facility + episodic
Persimmon Quest: [0.88, 0.84]
SOMPO + Palantir: [0.78, 0.58]
Nippontect ONSEI: [0.55, 0.38]
Eisai NouKNOW: [0.42, 0.34]
Neeuro: [0.58, 0.67]
PENSIEVE-AI: [0.50, 0.28]
Muse: [0.22, 0.70]
Myndlift: [0.28, 0.72]
EMOTIV: [0.36, 0.54]
Altoida: [0.35, 0.22]
Ai-BrainScience: [0.48, 0.18]
Flow: [0.18, 0.42]
Neuroelectrics: [0.23, 0.26]
Cognito: [0.16, 0.24]
The placement above is analytical projection. It reflects how each company publicly positions its product: Muse and Myndlift are much more daily than hospital tools, but they are not facility-native; Ai-BrainScience and Altoida are cognitively relevant, but they are still more episodic and clinical than PQ; SOMPO + Palantir is very facility-native, but it is not a resident-facing daily brain-health layer.